Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Prioty Islam, MD, MSc, discusses the exploration of novel roles for BTK inhibitors in the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia.
Harry P. Erba, MD, PhD, discusses the implications of the FDA approval of quizartinib for the treatment of patients with FLT3-ITD–mutated AML, the background and key findings of the QuANTUM-First study, and how to now navigate between potential treatment options for this patient population.
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the...
Nausheen Ahmed, MD, discusses the rationale for investigating real-world outcomes of patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.
FOR IMMEDIATE RELEASE 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational...